Latest KFF Health News Stories
This Panel Will Decide Whose Medicine to Make Affordable. Its Choice Will Be Tricky.
Colorado’s new Prescription Drug Affordability Board could cap what health plans and consumers pay for certain medications starting next year. The process will pit patient groups against one another.
A More Aggressive FTC Is Starting to Target Drug Mergers and Industry Middlemen
Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by then-President Donald Trump.
La Comisión Federal de Comercio está actuando contra las empresas farmacéuticas y los intermediarios del sector, como parte de la campaña de la administración Biden para reducir los precios de los medicamentos en las farmacias.
Are US Prescription Drug Prices 10 Times Those of Other Nations? Only Sometimes
Sen. Bernie Sanders’ broad statement that some U.S. drug prices are 10 times those of other nations doesn’t paint the full picture. Studies we examined generally found that U.S. prices were two to four times those in other countries, not 10.
PBMs, the Brokers Who Control Drug Prices, Finally Get Washington’s Attention
Drugmakers, pharmacies, and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?
California Confronts Overdose Epidemic Among Former Prison Inmates
Individuals newly released from prison are 40 times as likely to die of opioid overdoses than members of the general population, researchers say. In response, California corrections officials aim to arm departing inmates with an antidote that can be used to reverse the effects of opioid poisoning.
KFF Health News' 'What the Health?': Will They or Won’t They (Block the Abortion Pill)?
The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.
Redes sociales alimentan obsesión por las drogas para bajar de peso, sin hablar de riesgos
La competencia para hacerse con un mercado que podría valer $100.000 millones al año, solo para los fabricantes de medicamentos, ha desencadenado una ola de publicidad que preocupa a las autoridades sanitarias y médicos de todo el mundo.
Social Media Is Fueling Enthusiasm for New Weight Loss Drugs. Are Regulators Watching?
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
Journalists Track Opioid Settlement Cash and Fees for Telehealth Visits
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
La empresa farmacéutica que prosperó sin crear ni un solo medicamento
Aunque Horizon afirma que ahora tiene 20 fármacos en desarrollo, en sus 15 años de existencia aún no ha obtenido la licencia de un producto de su creación.
The Drug Company That Prospered Without Creating Any Drugs
Horizon Therapeutics, which Amgen is acquiring for about $28 billion, grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.
Truly Random Drug Testing: ADHD Patients Face Uneven Urine Screens and, Sometimes, Stigma
Doctors have no national standards on when to order urine tests to check whether adult ADHD patients are properly taking their prescription stimulants. Some patients are subjected to much more frequent testing than others.
Journalists Delve Into Insulin Costs and Prior Authorization Policy
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Fresh Produce Is an Increasingly Popular Prescription for Chronically Ill Patients
Fresh produce prescription programs are getting a boost in Montana as a way of helping people with chronic conditions such as diabetes and high blood pressure. The approach may be a model for other rural states to promote healthy eating in food deserts.
¿Ayudan las nuevas guías sobre opioides a los pacientes con dolor crónico?
Las recomendaciones dejaron a muchos pacientes lidiando con las consecuencias para la salud mental y física de la reducción rápida de la dosis o la suspensión abrupta de los medicamentos que habían estado tomando durante años, lo que conlleva riesgos de abstinencia, depresión e incluso suicidio.
New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?
In November, the Centers for Disease Control and Prevention released new guidelines for prescribing opioids for pain, allowing physicians more flexibility. But doctors, patients, and advocates wonder if the updated standards will be too little, too late to help chronic pain patients in a country still focused on fighting the ongoing opioid crisis.
La insulina representa lo perverso del sistema sanitario estadounidense, ya que los precios de venta de este medicamento centenario, del que dependen 8,4 millones de estadounidenses para sobrevivir, se quintuplicaron en dos décadas.
Why Does Insulin Cost So Much? Big Pharma Isn’t the Only Player Driving Prices
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it’s the arbitrators that jack up prices for those who can least afford them.
Envíos ilegales de medicamentos por correo no son de opioides. Muchos contienen Viagra genérico
Los funcionarios de la FDA afirman que los medicamentos comprados en farmacias extranjeras tienen 10 veces más probabilidades de ser falsificados que los vendidos en Estados Unidos.
